Skip to search formSkip to main contentSkip to account menu

sitaxsentan

Known as: N-(4-chloro-3-methyl-5-isoxazolyl)-2-((4,5-(methylenedioxy)-O-toly)acetyl)-3-thiophenesulfonamide, N-(4-chloro-3-methyl-5-isoxazolyl)-2-(3,4-(methylenedioxy)-6-methyl)phenylacetyl-3-thiophenesulfonamide, SITAXENTAN 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (3)

Endothelin receptor antagonistIsoxazolesThiophenes

Narrower (1)

TBC-11251

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Comparative efficacy and acceptability of endothelin receptor antagonists for pulmonary arterial hypertension: A network meta-analysis.
2014
2014
Endothelin antagonism and uric acid levels in pulmonary arterial hypertension: clinical associations.
2012
2012
Defining the affinity and receptor sub-type selectivity of four classes of endothelin antagonists in clinically relevant human cardiovascular tissues.
2010
2010
Greater Functional ETB Receptor Antagonism With Bosentan Than Sitaxsentan in Healthy Men
Endothelin (ET)-1 is implicated in the development of hypertension and a role for endothelin receptor antagonists (ETRAs) in the… 
Review
2009
Review
2009
Bleeding events in pulmonary arterial hypertension
Despite limited evidence from clinical studies, anticoagulant drugs such as vitamin K antagonists (VKA) (e.g., warfarin or… 
Review
2008
Review
2008
Pulmonary arterial hypertension: on the way to a manageable disease.
Pulmonary arterial hypertension (PAH) is an orphan disease for which no specific pharmacological therapy was available until 1996… 
2007
2007
Cost-Utility of Treatments for Pulmonary Arterial Hypertension
AbstractBackground and Objective: Clinicians must choose between an increasing number of medications for the treatment of… 
Review
2007
Review
2007
Sitaxsentan: a selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a progressive, life-threatening condition. Sitaxsentan, a selective endothelin-A… 
Review
2002
Review
2002
Emerging medical therapies for pulmonary arterial hypertension.
Until a few years ago, "conventional" treatment for pulmonary arterial hypertension (PAH) included oral anticoagulants, calcium… 
Review
2001
Review
2001
Clinical Experience with Endothelin Receptor Antagonists in Chronic Heart Failure
Abstract: Both ETA selective and dual, ETA/B, receptor antagonists have favourable short- and longer-term haemodynamic actions in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)